Inactive Instrument

StemCells Inc Stock Nasdaq

Equities

US85857R2040

Biotechnology & Medical Research

End-of-day quote Nasdaq
- USD - Intraday chart for StemCells Inc
Sales 2024 * - Sales 2025 * - Capitalization 17.48M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.48%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 52 88-08-01
Director of Finance/CFO 45 21-12-31
Chief Tech/Sci/R&D Officer - Nov. 30
Members of the board TitleAgeSince
Director/Board Member 59 16-11-27
Director/Board Member 66 17-12-11
Director/Board Member 50 20-07-31
More insiders
Microbot Medical Inc. is a pre-clinical medical device company. The Company is specializing in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. It is primarily focused on leveraging its robotic technologies with surgical robotics to improve surgical outcomes for patients. Its technological platforms include LIBERTY and NovaCross. Using its LIBERTY Endovascular Robotic Surgical System, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. LIBERTY Endovascular Robotic Surgical System addresses the needs of interventional cardiology, interventional radiology and interventional neuroradiology markets.
More about the company